Ardena cements growth and expansion with new HQ

12 Nov 2018

Larger headquarters will enable the company to free up space for additional laboratories and further expand capabilities.

CDMO Ardena has cemented a sustained period of growth with a move to expanded headquarters in Gent, Belgium.

Ardena cements growth and expansion with new HQ

Since 2015, Ardena has grown from 40 to 250 staff members and seen more than 20% organic growth per year, fueled by the CDMO’s M&A strategy which has seen four acquisitions in the past 2 years, most recently Netherlands-based ChemConnection and Sweden-based Syntagon.

It now operates across six sites in Belgium, the Netherlands, Sweden and Latvia and boasts a global reach, servicing more than 300 customers in Europe, the US, Japan and Korea.

Ardena offers integrated drug development services encompassing drug substance and drug product development, clinical manufacturing, clinical logistics, full product analytical and bioanalytical support and regulatory dossier development. The company is also a leader in nanomedicine technology.

Harry Christiaens, CEO at Ardena said: “After several acquisitions and an ongoing growth period, we are firmly on track to reach our €35 million sales target for 2018 as part of our wider strategy to become a leading integrated drug development company.

“This new, larger headquarters will enable us to free up space for additional laboratories at our other sites and further expand our capabilities. It will also provide a base for our staff training centre to ensure we develop our team.

“As we move into 2019, we look forward to continued international success and carrying on with our acquisition strategy to further strengthen our service offering.”

Ardena was formed in 2017, following the merging of three companies with complementary drug development capabilities: Pharmavize in Belgium, and Crystallics and Analytical Biochemical Laboratory (ABL) in the Netherlands.

Read More

Related news

Allergan to establish R&D presence in Cambridge, Massachusetts

Allergan to establish R&D presence in Cambridge, Massachusetts

10 Jan 2019

The new, strategic presence will allow the company to more easily interact and engage with venture firms and start ups in the area.

Read more 
Expedeon signs supply and license agreement for is Lightning-Link technology

Expedeon signs supply and license agreement for is Lightning-Link technology

9 Jan 2019

The technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results.

Read more 
Lilly to bag Loxo Oncology for $8 billion

Lilly to bag Loxo Oncology for $8 billion

8 Jan 2019

Acquisition will broaden the scope of Lilly's oncology portfolio into precision medicines.

Read more 
Catalent to double its commercial biomanufacturing capacity

Catalent to double its commercial biomanufacturing capacity

7 Jan 2019

The $200-million expansion will support customers’ development programs and commercial launches.

Read more 
BMS and Celgene merge to create premier innovative biopharma company

BMS and Celgene merge to create premier innovative biopharma company

3 Jan 2019

Significantly expands Phase III assets with six expected near-term product launches, representing greater than $15 billion in revenue potential.

Read more 
Cambrex completes acquisition of Avista Pharma Solutions

Cambrex completes acquisition of Avista Pharma Solutions

2 Jan 2019

Acquisition adds a full complement of early-stage development capabilities to Cambrex’s larger scale capabilities for APIs and finished dosage forms.

Read more 
Novartis offers to acquire CellforCure

Novartis offers to acquire CellforCure

1 Jan 2019

Proposed acquisition will expand manufacturing capacity for innovative cell and gene therapies.

Read more 
BMS receives offer from Taisho to purchase UPSA

BMS receives offer from Taisho to purchase UPSA

30 Dec 2018

The potential transaction would position BMS to further refine its portfolio to focus on transformational medicines for patients facing serious diseases.

Read more 
Recipharm to potentially end operations in Ashton-under-Lyne facility

Recipharm to potentially end operations in Ashton-under-Lyne facility

24 Dec 2018

The operation has not been profitable for several years; no likely prospect of it being able to deliver an acceptable return in the medium term.

Read more 
An increased risk of a hard or ‘no deal Brexit?

An increased risk of a hard or ‘no deal Brexit?

24 Dec 2018

A ‘no deal’ Brexit will change and burden how all industries that move materials and goods across borders, including the pharmaceutical and medical device sectors, do business.

Read more